Toxic liver disease with chronic active hepatitis with ascites
ICD-10 K71.51 is a billable code used to indicate a diagnosis of toxic liver disease with chronic active hepatitis with ascites.
K71.51 refers to toxic liver disease characterized by chronic active hepatitis accompanied by ascites. This condition arises from exposure to hepatotoxic substances, leading to inflammation and damage to liver cells. Clinically, patients may present with symptoms such as jaundice, fatigue, abdominal pain, and fluid accumulation in the abdominal cavity (ascites). The liver, a vital organ in the digestive system, plays a crucial role in metabolism, detoxification, and bile production. Chronic active hepatitis indicates ongoing inflammation, which can progress to fibrosis and cirrhosis if left untreated. Diagnostic considerations include liver function tests, imaging studies (such as ultrasound or CT scans), and liver biopsy to assess the extent of damage and rule out other liver diseases. The management of K71.51 often involves addressing the underlying cause of toxicity, monitoring liver function, and managing complications such as ascites through diuretics or paracentesis. Regular follow-up is essential to monitor disease progression and adjust treatment as necessary.
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
Standard ICD-10-CM documentation requirements apply
Various clinical presentations within this specialty area
Follow specialty-specific billing guidelines
K71.51 covers toxic liver disease resulting from exposure to harmful substances leading to chronic active hepatitis and the presence of ascites. This includes conditions related to alcohol, medications, and environmental toxins.
K71.51 should be used when there is clear documentation of chronic active hepatitis with ascites due to toxic liver disease. It is essential to differentiate it from other liver conditions that may not involve ascites or chronic inflammation.
Documentation should include a detailed patient history of toxic exposure, laboratory results indicating liver dysfunction, imaging studies showing ascites, and clinical assessments that confirm chronic active hepatitis.
